Skip to main content
رجوع
ABVX logo

Abivax S.A.

جودة البيانات: 100%
ABVX
NASDAQ Healthcare Biotechnology
KWD 115.42
▼ KWD 4.92 (-4.09%)
القيمة السوقية: 7.57B
مُدرج أيضًا باسم AAVXF OTC
نطاق اليوم
KWD 115.02 KWD 122.97
نطاق 52 أسبوعًا
KWD 4.77 KWD 148.83
حجم التداول
1,265,517
متوسط 50 يوم / 200 يوم
KWD 119.11 / KWD 87.46
الإغلاق السابق
KWD 120.34

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -42.9 0.4
P/B 186.5 2.9
ROE % -149.0 3.7
Net Margin % -1633.1 3.9
Rev Growth 5Y % 261.8 10.0
D/E 2.4 0.2

السعر المستهدف للمحللين

Hold
KWD 142.500 +23.5%
Low: KWD 110.000 High: KWD 176.000
ربحية السهم المستقبلية
-KWD 3.066
الإيرادات المقدّرة
3.8 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 4.963
KWD 3.054 – KWD 6.873
1.5 B 1
FY2029 KWD 5.349
KWD 3.291 – KWD 7.407
1.2 B 1
FY2028 KWD 0.710
KWD 0.312 – KWD 1.108
570 M 2

النقاط الرئيسية

Revenue grew 261.78% annually over 5 years — strong growth
Debt/Equity of 2.40 — high leverage
Negative free cash flow of -154.72M
PEG of 0.14 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 128.24%
Capital efficient — spends only 5.96% of revenue on capex

النمو

Revenue Growth (5Y)
261.78%
Revenue (1Y)133.54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-148.98%
ROIC-94.05%
Net Margin-1633.08%
Op. Margin-1602.89%

الأمان

Debt / Equity
2.40
Current Ratio1.84
Interest Coverage-41.33

التقييم

P/E Ratio
-42.94
P/B Ratio186.47
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 133.54% Revenue Growth (3Y) 53.45%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 261.78% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10.79M Net Income (TTM) -176.24M
ROE -148.98% ROA -85.88%
Gross Margin 100.00% Operating Margin -1602.89%
Net Margin -1633.08% Free Cash Flow (TTM) -154.72M
ROIC -94.05% FCF Growth (3Y) N/A
Safety
Debt / Equity 2.40 Current Ratio 1.84
Interest Coverage -41.33 Dividend Yield 0.00%
Valuation
P/E Ratio -42.94 P/B Ratio 186.47
P/S Ratio 701.25 PEG Ratio 0.14
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 7.57B Enterprise Value 7.52B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 10.79M 4.62M 4.58M 37,000.0 63,000.0
Net Income -176.24M -147.74M -60.74M -42.45M -37.55M
EPS (Diluted) -2.80 -3.43 -3.18 -2.75 -2.62
Gross Profit 10.79M 4.57M 4.47M -119,000.0 -33.77M
Operating Income -172.98M -127.38M -64.84M -41.40M -38.01M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 205.23M 327.06M 75.54M 109.23M 71.30M
Total Liabilities 164.64M 131.05M 68.36M 83.30M 53.40M
Shareholders' Equity 40.58M 196.01M 7.19M 25.93M 17.90M
Total Debt 97.36M 58.04M 39.16M 51.65M 33.99M
Cash & Equivalents 144.22M 251.94M 26.95M 60.70M 29.30M
Current Assets 170.67M 285.97M 36.18M 75.21M 37.67M
Current Liabilities 92.83M 88.12M 51.46M 32.26M 19.41M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#5 of 146
77

النشاط الأخير

دخل Full Throttle
Mar 24, 2026